(Sharecast News) - GSK on Tuesday said its treatment for small-cell lung cancer (SCLC) had received orphan drug status from the European Medicines Agency.
The antibody-drug conjugate is known as GSK'227 and the designation was supported by preliminary clinical data showing durable responses in patients with extensive stage SCLC who were...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE